Value of three-dimensional speckle tracking echocardiography to assess left ventricular function in hyperuricemia patients

To assess the value of three-dimensional speckle tracking echocardiography (3D STE) in evaluating the left ventricular (LV) function in hyperuricemia patients. We enrolled 15 healthy controls and 40 hyperuricemia patients and collected and analyzed full-volume 3D STE images of the left ventricle in the apical four-chamber heart view. Laboratory tests and 3D STE parameters, including left ventricular ejection fraction, left ventricular end-diastolic volume, left ventricular end-systolic volume, stroke volume (SV), global longitudinal strain (GLS), and global circumferential strain (GCS), were compared between hyperuricemia patients and healthy controls. Hypenuicemia patients exhibited higher body mass index (24.70 +/- 2.9 vs. 21.83 +/- 2.4 kg/m(2), p = 0.001), C-reactive protein (5.82 +/- 9.4 vs. 1.12 +/- 1.8 g/L, p = 0.012), alanine transaminase (34.26 +/- 26.6 vs. 17.60 +/- 13.0 U/L, p = 0.011), aspartate transaminase (24.90 +/- 11.3 vs. 17.70 +/- 4.1 U/L, p = 0.001), blood urea nitrogen (5.11 +/- 1.6 vs. 4.18 +/- 0.6 mmol/ L, p= 0.046), and serum creatinine (90.25 +/- 14.6 vs. 77.93 +/- 10.8 mu mol/L, p= 0.006) levels, as well as a lower estimated glomerular filtration rate (87.87 +/- 16.5 vs. 103.64 +/- 11.3 mL/min/1.73m(2), p= 0.002). The 3D STE parameters reflecting LV function, including SV (54.71 +/- 9.6 vs. 61.92 +/- 14.4 mL, p= 0.024), GLS (- 20.51 +/- 4.0 vs. - 23.20 +/- 4.0%, p = 0.019), and GCS (- 31.30 +/- 5.0 vs. - 35.65 +/- 2.5%, p = 0.000), were significantly decreased in hyperuricemia patients. Furthermore, GCS was significantly correlated with the serum uric acid (sUA) level even after adjustment of confounding variables like age, body mass index, and serum creatinine. 3D STE is a novel technique for recognizing the early decline in LV function, with GLS and GCS serving as reliable indicators, in hyperuricemia patients. Moreover, the degree of decline in LV function may be conflated with the sUA level in hyperuricemia patients.